SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Safety and effectiveness of long-acting injectable Aripiprazole in daily practice: A naturalistic retrospective study

Dawood, S; Smith, JG; Nadeem, N; Abbasian, C (2020) Safety and effectiveness of long-acting injectable Aripiprazole in daily practice: A naturalistic retrospective study. The European Journal of Psychiatry, 34 (2). pp. 82-89. ISSN 0213-6163 https://doi.org/10.1016/j.ejpsy.2020.02.001
SGUL Authors: Smith, Jared Grant

[img] PDF Accepted Version
Restricted to Repository staff only until 3 May 2021.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (637kB)

Abstract

Background and objectives It was postulated that Aripiprazole may cause impulse-control problems. Therefore, real-world data on the effects and side effects of Aripiprazole 400 mg depot are needed to review the utility, safety and the clinical effectiveness of Aripriprazole 400 mg depot and highlight the occurrence of adverse effects including impulsivity in a naturalistic treatment settings. Methods A non-interventional, retrospective study was conducted to examine the electronic records of all patients who were receiving or had received Aripiprazole Lauroxil in South West London before May 2017. Disorder symptoms and side effects were compared between pre- and post-Aripiprazole PO and Aripiprazole Depot treatments. Results Data were considered for 57 patients who switched to Aripiprazole depot due to non-compliance and/or side effects. Most were suffering from chronic schizophrenia (75.4 %) and half (50.9 %) had comorbid alcohol and/or illicit drug use. Oral Aripiprazole was effective in improving hallucinations, delusions and depressive symptoms (P < 0.022); these benefits were maintained or enhanced further with Aripiprazole Depot. Proportions of patients experiencing sexual disinhibition, aggression and deliberate self-ham decreased significantly (P < 0.003) after starting oral Aripiprazole with no further change after Aripiprazole Depot. By study end, a quarter of patients had stopped taking Aripiprazole Depot due to ineffectiveness, side effects or patient request. Conclusion Aripriprazole Lauroxil 400 mg depot was safe, effective and well tolerated. Side effects manifestations should prompt full evaluations and dose reduction should be considered.

Item Type: Article
Additional Information: © 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: 1103 Clinical Sciences, Psychiatry
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
Journal or Publication Title: The European Journal of Psychiatry
ISSN: 0213-6163
Dates:
DateEvent
April 2020Published
3 May 2020Published Online
4 February 2020Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
URI: http://openaccess.sgul.ac.uk/id/eprint/111733
Publisher's version: https://doi.org/10.1016/j.ejpsy.2020.02.001

Actions (login required)

Edit Item Edit Item